Thanks to donations from thousands of people, including a large
donation of two million Swiss franc from entrepreneur Vince
Hamilton, the Oncolytic Virus Fund has reached an important
milestone. The fund has collected enough money for Professor
Magnus Essand and his research group to start work with the
world’s first clinical trials of a virus treatment specifically
engineered to target neuroendocrine tumours. While this
constitutes a large and important achievment for the project,
further donations are vital to keep the research moving forward.
Professor Magnus Essand at Uppsala University has during six
years developed and tested a potentially new treatment against
neuroendocrine tumours. The treatment consists of an oncolytic
virus, which has turned out to be remarkably efficient in
destroying neuroendocrine tumours in mice. With enough funding
he will be able to start the world’s first human trials with a
genetically engineered virus specifically designed to target
neuroendocrine tumours. What is an oncol